Login / Signup

Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.

Qingnan ZhaoJiemiao HuAbhisek MitraJeffry CutreraWendong ZhangZhongting ZhangJun YanXueqing XiaKris Michael MahadeoJohn Andrew LivingstonRichard GorlickShulin Li
Published in: Journal for immunotherapy of cancer (2019)
ttIL-12 when combined with surgery led to conversion to the IFNγHiCD8HiFOXP3LowCD33Low immune profile, eliminated relapse and metastasis, and prolonged overall survival.
Keyphrases
  • free survival
  • minimally invasive
  • immune response
  • coronary artery bypass
  • dendritic cells
  • drug delivery
  • coronary artery disease
  • acute coronary syndrome